New hope for PNH: crovalimab shows promise in controlling red blood cell destruction

NCT ID NCT04654468

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 08, 2026 · Updated 23 times

Summary

This study tests a new drug, crovalimab, in about 50 people aged 12 and older with PNH, a rare blood disorder that destroys red blood cells. Participants have not received similar treatments before. The goal is to see if crovalimab can control the breakdown of red blood cells and reduce the need for blood transfusions over 24 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Institute of Hematology and Hospital of Blood Disease

Tianjin, 300020, China
Tianjin Medical University General Hospital

Tianjin, 300052, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, 430022, China
West China Hospital, Sichuan University

Chengdu, 610041, China

Conditions

Explore the condition pages connected to this study.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA